Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic ewing family tumors or desmoplastic small round cell tumors Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Bone Neoplasms
  • Desmoplastic Small Round Cell Tumor
  • Receptor, IGF Type 1
  • Sarcoma, Ewing

abstract

  • Ganitumab was well tolerated and demonstrated antitumor activity in patients with advanced recurrent EFT or DSRCT.

publication date

  • May 20, 2012

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2011.37.2359

PubMed ID

  • 22508822

Additional Document Info

start page

  • 1849

end page

  • 56

volume

  • 30

number

  • 15